Navigation Links
3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
Date:5/1/2013

SHENYANG, China, May 1, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has filed the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2012 with the U.S. Security and Exchange Commission on April 30, 2013. The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov or on the Investor section of the Company's website www.3sbio.com. Shareholders may also receive a hard copy of the annual report free of charge upon request.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Investor Contacts

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com  

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
2. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
3. 3SBio Inc. Announces Unaudited First Quarter 2012 Results
4. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
5. 3SBio Inc. to Present at the UBS Greater China Conference 2012
6. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
7. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
8. TNI BioTech Files Form 10 with SEC
9. Marrone Bio Innovations Files Patent for a Unique Bacillus Species
10. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
11. NDIS Approval of the Promega PowerPlex(R) Y23 System Enables More Usable Profiles in Less Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... LANSING, Mich. , Dec. 7, 2016 ... it has named Dr. Dan Kephart as ... the company. Kephart will assume his responsibilities at Neogen ... research and development director for the agribusiness unit of ... food safety development at Life Technologies. His extensive industry ...
(Date:12/7/2016)... 7, 2016  Nordion, a standalone business of ... welcome today,s award by the United States Department ... of the Phase II cooperative agreement funding to ... the University of Missouri Research Reactor Center (MURR ... the establishment of a new, reliable supply of ...
(Date:12/7/2016)... 2016  Vyriad Inc. announced today the appointment of ... of Directors. "We are delighted to welcome ... and develop our oncolytic viruses as the next generation ... Russell , MD, PhD, CEO of Vyriad. "Al and ... and passion for making a difference for cancer patients—their ...
Breaking Biology Technology:
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
Breaking Biology News(10 mins):